Alteration of the Expression and Functional Activities of Myosin II Isoforms in Enlarged Hyperplastic Prostates

Overview

Journal J Pers Med

Date 2024 Apr 27

PMID 38673008

Authors

Xiao Wang

Weixiang He

Hui Chen

Rui Yang

Hongmei Su

Michael E DiSanto

Xinhua Zhang

Affiliations

Soon will be listed here.

Abstract

Introduction: Benign prostatic hyperplasia (BPH) is a common pathologic process in aging men, and the contraction of the prostatic smooth muscles (SMs) in the stroma plays a vital role in this pathogenesis, leading to lower urinary tract symptoms (LUTSs). The isoforms of both the SM myosin (SMM) and non-muscle myosin (NMM) are associated with the contraction type of the prostatic SMs, but the mechanism has not been fully elucidated.

Methods: We collected prostate tissues from 30 BPH patients receiving surgical treatments, and normal human prostate samples were obtained from 12 brain-dead men. A testosterone-induced (T-induced) rat model was built, and the epithelial hyperplastic prostates were harvested. Competitive RT-PCR was used to detect the expression of SMM isoforms. We investigated the contractility of human prostate strips in vitro in an organ bath.

Results: The results regarding the comparisons of SMM isoforms varied between rat models and human samples. In comparison with T-induced rats and controls, competitive RT-PCR failed to show any statistically significant difference regarding the compositions of SMM isoforms. For human prostates samples, BPH patients expressed more SM-1 isoforms (66.8% vs. 60.0%, < 0.001) and myosin light chain-17b (MLC) (35.9% vs. 28.5%, < 0.05) when compared to young donors. There was a significant decrease in prostate myosin heavy chain (MHC) expression in BPH patients, with a 66.4% decrease in MHC at the mRNA level and a 51.2% decrease at the protein level. The upregulated expression of non-muscle myosin heavy chain-B (NMMHC-B) was 1.6-fold at the mRNA level and 2.1-fold at the protein level. The organ bath study showed that isolated prostate strips from BPH patients produced slower tonic contraction compared to normal humans.

Conclusion: In this study, we claim that in the enlarged prostates of patients undergoing surgeries, MHC expression significantly decreased compared to normal tissues, with elevated levels of SM-1, MLC, and NMMHC-B isoforms. Modifications in SMM and NMM might play a role in the tonic contractile properties of prostatic SMs and the development of LUTS/BPH. Understanding this mechanism might provide insights into the origins of LUTS/BPH and facilitate the identification of novel therapeutic targets.

References

Wang L, Chitano P, Seow C . Filament evanescence of myosin II and smooth muscle function. J Gen Physiol. 2021; 153(3). PMC: 7901143. DOI: 10.1085/jgp.202012781. View

Yuen S, Ogut O, Brozovich F . Nonmuscle myosin is regulated during smooth muscle contraction. Am J Physiol Heart Circ Physiol. 2009; 297(1):H191-9. PMC: 2711724. DOI: 10.1152/ajpheart.00132.2009. View

Sanches B, Maldarine J, Vilamaior P, Felisbino S, Carvalho H, Taboga S . Stromal cell interplay in prostate development, physiology, and pathological conditions. Prostate. 2021; 81(13):926-937. DOI: 10.1002/pros.24196. View

Liu Y, Wang R, Huang R, Rutz B, Ciotkowska A, Tamalunas A . Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003. Front Pharmacol. 2023; 14:1105427. PMC: 10175612. DOI: 10.3389/fphar.2023.1105427. View

Tamalunas A, Sauckel C, Ciotkowska A, Rutz B, Wang R, Huang R . Lenalidomide and pomalidomide inhibit growth of prostate stromal cells and human prostate smooth muscle contraction. Life Sci. 2021; 281:119771. DOI: 10.1016/j.lfs.2021.119771. View

Spek A, Li B, Rutz B, Ciotkowska A, Huang R, Liu Y . Purinergic smooth muscle contractions in the human prostate: estimation of relevance and characterization of different agonists. Naunyn Schmiedebergs Arch Pharmacol. 2021; 394(6):1113-1131. PMC: 8208936. DOI: 10.1007/s00210-020-02044-4. View

Zhang W, Zang N, Jiang Y, Chen P, Wang X, Zhang X . Upregulation of Phosphodiesterase type 5 in the Hyperplastic Prostate. Sci Rep. 2015; 5:17888. PMC: 4674741. DOI: 10.1038/srep17888. View

Joseph D, Henry G, Malewska A, Reese J, Mauck R, Gahan J . Single-cell analysis of mouse and human prostate reveals novel fibroblasts with specialized distribution and microenvironment interactions. J Pathol. 2021; 255(2):141-154. PMC: 8429220. DOI: 10.1002/path.5751. View

Dey S, Singh R, Chattoraj S, Saha S, Das A, Bhattacharyya K . Differential role of nonmuscle myosin II isoforms during blebbing of MCF-7 cells. Mol Biol Cell. 2017; 28(8):1034-1042. PMC: 5391180. DOI: 10.1091/mbc.E16-07-0524. View

10.

Zhang X, Zang N, Wei Y, Yin J, Teng R, Seftel A . Testosterone regulates smooth muscle contractile pathways in the rat prostate: emphasis on PDE5 signaling. Am J Physiol Endocrinol Metab. 2011; 302(2):E243-53. PMC: 3340899. DOI: 10.1152/ajpendo.00458.2011. View

11.

Andriole G, Bruchovsky N, Chung L, Matsumoto A, Rittmaster R, Roehrborn C . Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol. 2004; 172(4 Pt 1):1399-403. DOI: 10.1097/01.ju.0000139539.94828.29. View

12.

Cao D, Sun R, Peng L, Li J, Huang Y, Chen Z . Immune Cell Proinflammatory Microenvironment and Androgen-Related Metabolic Regulation During Benign Prostatic Hyperplasia in Aging. Front Immunol. 2022; 13:842008. PMC: 8977548. DOI: 10.3389/fimmu.2022.842008. View

13.

Liu J, Zhang J, Fu X, Yang S, Li Y, Liu J . The Emerging Role of Cell Adhesion Molecules on Benign Prostatic Hyperplasia. Int J Mol Sci. 2023; 24(3). PMC: 9917596. DOI: 10.3390/ijms24032870. View

14.

Zhang N, Li Z, Bai F, Ji N, Zheng Y, Li Y . MicroRNA expression profiles in benign prostatic hyperplasia. Mol Med Rep. 2018; 17(3):3853-3858. DOI: 10.3892/mmr.2017.8318. View

15.

Sun J, Qiao Y, Tao T, Zhao W, Wei L, Li Y . Distinct Roles of Smooth Muscle and Non-muscle Myosin Light Chain-Mediated Smooth Muscle Contraction. Front Physiol. 2021; 11:593966. PMC: 7793928. DOI: 10.3389/fphys.2020.593966. View

16.

Isaacs J . Prostate stem cells and benign prostatic hyperplasia. Prostate. 2008; 68(9):1025-34. PMC: 3350783. DOI: 10.1002/pros.20763. View

17.

Tamalunas A, Sauckel C, Ciotkowska A, Rutz B, Wang R, Huang R . Inhibition of human prostate stromal cell growth and smooth muscle contraction by thalidomide: A novel remedy in LUTS?. Prostate. 2021; 81(7):377-389. DOI: 10.1002/pros.24114. View

18.

Castro P, Giri D, Lamb D, Ittmann M . Cellular senescence in the pathogenesis of benign prostatic hyperplasia. Prostate. 2003; 55(1):30-8. DOI: 10.1002/pros.10204. View

19.

Janky R, Verfaillie A, Imrichova H, Van de Sande B, Standaert L, Christiaens V . iRegulon: from a gene list to a gene regulatory network using large motif and track collections. PLoS Comput Biol. 2014; 10(7):e1003731. PMC: 4109854. DOI: 10.1371/journal.pcbi.1003731. View

20.

Thiyagarajan M, Kaul C, Ramarao P . Enhancement of alpha-adrenoceptor-mediated responses in prostate of testosterone-treated rat. Eur J Pharmacol. 2002; 453(2-3):335-44. DOI: 10.1016/s0014-2999(02)02452-4. View